Funder
University of Texas MD Anderson Cancer Center
Cancer Prevention and Research Institute of Texas
Subject
Cancer Research,Oncology,Hematology
Reference32 articles.
1. National Cancer Institute. 2020 Surveillance, epidemiology, and end results program, Cancer Stat Facts, https://seer.cancer.gov/statfacts/. Published 2020. Accessed June 23 2020.
2. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin,2016
3. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study;Flinn;J Clin Oncol,2019
4. Obinutuzumab for the first-line treatment of follicular lymphoma;Marcus;N Engl J Med,2017
5. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial;Rummel;Lancet,2013
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献